ArticleJournal of the American Society of Nephrology : JASN2012
Cost-effectiveness of screening for microalbuminuria among African Americans.
Article in Journal of the American Society of Nephrology : JASN, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03832166 (A Prospective, Randomized Two Group Study to Evaluate the Feasibility and Initial Efficacy of a Community-engaged Screening, Identification, and F&V Intervention to Improve F&V Intake and CKD Outcomes in 140 AA Adults), which is not on this map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Randomized Two Group Study to Evaluate the Feasibility and Initial Efficacy of a Community-engaged Screening, Identification, and F&V Intervention to Improve F&V Intake and CKD Outcomes in 140 AA Adults
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Screening for chronic kidney disease: a systematic review of emerging evidence and perspectives.Renal failure · 2025Pooled it
- Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design.PharmacoEconomics · 2019Pooled it
- Methods Used in Economic Evaluations of Chronic Kidney Disease Testing - A Systematic Review.PloS one · 2015Pooled it
- Implementation of a pragmatic randomized trial of screening for chronic kidney disease to improve care among non-diabetic hypertensive veterans.BMC nephrology · 2017Trial
- The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese non-diabetic patients.Clinical and experimental nephrology · 2025Article
- Cost-effectiveness of population-based screening for chronic kidney disease among the general population and adults with diabetes in China: a modelling study.The Lancet regional health. Western Pacific · 2025Article
- The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes.Journal of diabetes investigation · 2025Article
- Examining chronic kidney disease screening frequency among diabetics: a POMDP approach.Health care management science · 2024Article
- Accuracy of glomerular filtration rate estimation using creatinine and cystatin C for identifying and monitoring moderate chronic kidney disease: the eGFR-C study.Health technology assessment (Winchester, England) · 2024Article
- Cost-effectiveness of screening for chronic kidney disease using a cumulative eGFR-based statistic.PloS one · 2024Article
- Cost-effectiveness of screening for chronic kidney disease in the general adult population: a systematic review.Clinical kidney journal · 2024Article
- The Fruit and Veggies for Kidney Health Study: A Prospective Randomized Trial.Kidney medicine · 2023Article
- Impact of point-of-care screening for hypertension, diabetes and progression of chronic kidney disease in rural Manitoba Indigenous communities.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2021Article
- A population health dietary intervention for African American adults with chronic kidney disease: The Fruit and Veggies for Kidney Health randomized study.Contemporary clinical trials communications · 2020Article
- The Landscape of Diabetic Kidney Disease in the United States.Current diabetes reports · 2018Review
- Article
- The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease.BMC nephrology · 2017Article
- APOL1 Genotype and Race Differences in Incident Albuminuria and Renal Function Decline.Journal of the American Society of Nephrology : JASN · 2016Article
- Article
- The future burden of CKD in the United States: a simulation model for the CDC CKD Initiative.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2015Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Compared with other racial groups, African Americans have a similar prevalence of CKD but are much more likely to progress to ESRD, suggesting that the cost-effectiveness of screening strategies requires dedicated study in this population. Here, we calibrated the CKD Health Policy Model so that it accurately forecasts the higher rates for ESRD observed for African Americans. We then used the calibrated model to estimate the cost-effectiveness of screening for microalbuminuria followed by treatment with angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers. Incorporating racial differences in risk factors did not fully explain the much higher lifetime incidence of ESRD among African Americans. Thus, to calibrate the model, we applied a 20% increase in the rate of GFR decline at stage 3 and a 60% increase in the rate of GFR decline at stage 4, which resulted in a model that closely reflects lifetime ESRD incidence among African Americans. Compared with usual care, screening African Americans for microalbuminuria at 10-, 5-, 2-, and 1-year intervals had incremental cost-effectiveness ratios of $9000, $11,000, $19,000, and $35,000 per quality-adjusted life year, respectively. Incremental cost-effectiveness ratios for the same screening intervals were higher for non-African Americans: $17,000, $23,000, $44,000, and $81,000 per quality-adjusted life year, respectively. In summary, these models suggest that screening African Americans for microalbuminuria at either 5- or 10-year intervals is highly cost-effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.